La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bausch Health Companies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bausch Health Companies..

Bausch Health Companies (NYSE:BHC) Azioni, Catena delle Opzioni

Bausch Health Companies

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

BAUSCH HEALTH COMPANIES ORD

WIIM

ALRM

Alarm.com shares are trading higher after Goldman Sachs raised its price target on the stock from $64 to $67.

Truist Securities analyst Tobey Sommer maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Buy and raises the price target from $46 to $54.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on GFL Environmental, Raises Price Target to $54

Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $39.63 million which beat the analyst consensus estimate of $38.50 million by 2.95 percent. This is a 25.00 percent decrease over sales of $52.85 million the same period last year.

Earnings

VSTA

Vasta Platform Q3 Adj $(0.10) Beats $(0.13) Estimate, Sales $39.63M Beat $38.50M Estimate

FIVN

Five9 shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $35 to $46. Needham also reiterated its Buy rating.

Benchmark analyst Mark Miller maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Buy and raises the price target from $240 to $245.

NVMI

Benchmark Maintains Buy on Nova, Raises Price Target to $245

CRESY

CRESUD S.A.C.I.F. y A. Q1 2025 EPS ARS(66.54) Vs ARS181.95 YoY

UPST

Upstart Holdings shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $31 to $85. Citigroup upgraded the stock from Neutral to Buy and raised its price target from $56 to $87.

Truist Securities analyst William Stein maintains Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) with a Hold and lowers the price target from $69 to $62.

DIOD

Truist Securities Maintains Hold on Diodes, Lowers Price Target to $62

Evolent Health shares are trading lower after Stephens & Co. downgraded the stock from Overweight to Equal-Weight and announced a price target of $16.

Benchmark analyst Mike Hickey maintains Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and raises the price target from $14 to $16.

SRAD

Benchmark Maintains Buy on Sportradar Gr, Raises Price Target to $16

Truist Securities analyst Keith Hughes maintains CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) with a Buy and raises the price target from $110 to $120.

Truist Securities Maintains Buy on CRH, Raises Price Target to $120

Scotiabank analyst Andres Coello maintains Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) with a Sector Outperform and lowers the price target from $9.4 to $8.3.

LILAK

Scotiabank Maintains Sector Outperform on Liberty Latin America, Lowers Price Target to $8.3

Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) said that its investment strategy in the United States remains unaffected despite Donald Trump&#8217;s recent election win.
The statement came after speculation about potential changes to its plans following Trump&#8217;s critical remarks on Taiwan&#8217;s semiconductor industry, SCMP <a target="_blank" href="https://www.scmp.com/tech/policy/article/3285673/taiwans-chipmaker-tsmc-says-us-investment-plan-unchanged-after-trumps-election?module=perpetual_scroll_0&amp;pgtype=article" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor, a major supplier to tech giants like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), is proceeding with its $65 billion investment in advanced semiconductor production facilities in Arizona.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution" rel="noreferrer noopener">AppLovin&#8217;s High Valuation and Expansion Beyond Gaming Prompt Analyst Caution</a>
Throughout his campaign, Trump accused Taiwan <a target="_blank" href="https://www.benzinga.com/news/24/11/41780976/chip-stocks-like-nvidia-broadcom-taiwan-semi-gain-after-trump-win-whats-going-on" rel="noreferrer noopener">of undermining the</a> U.S. chip industry.
In a podcast appearance last month, he criticized the Chips Act, labeling it &#8220;a poor strategy,&#8221; suggesting tariffs would have been a more practical approach than offering subsidies to wealthy corporations.
The Biden administration recently notified Congress about imminent <a target="_blank" href="https://www.benzinga.com/government/24/11/41811866/taiwan-semi-and-globalfoundries-finalize-major-us-funding-deals-eye-growth-in-chip-manufacturing" rel="noreferrer noopener">awards from the</a> Chips Act, expected to benefit Taiwan Semiconductor, GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>), and a third unnamed semiconductor company.
The Act incentivizes chipmakers to expand U.S. production, allocating $37 billion across 21 preliminary agreements.
Despite concerns over Trump&#8217;s criticism of the Chips Act, Taiwan Semiconductor&#8217;s stock has shown resilience. The stock gained further momentum following a surge in Nvidia&#8217;s share price.
Taiwan Semiconductor has notified its clients in mainland China that it will cease production of advanced chips for them. The decision affects customers seeking chip designs using 7-nanometer technology or smaller, SCMP <a target="_blank" href="https://www.scmp.com/tech/tech-war/article/3285805/tsmc-halts-advanced-chip-orders-mainland-china-after-us-export-curbs-evasion-source" rel="noreferrer noopener">cites</a> familiar sources. The notice reportedly takes effect next week.
Mainland China contributed 11% to Taiwan Semiconductor&#8217;s third-quarter revenue, whereas North America accounted for 71%, SCMP cites Visible Alpha by S&amp;P Global Market Intelligence data.
Taiwan Semiconductor posted <a target="_blank" href="https://www.benzinga.com//node/41373163" rel="noreferrer noopener">fiscal third-quarter revenue</a> of 759.69 billion New Taiwan dollars ($23.50 billion), marking a 39% increase and surpassing both its guidance range of $22.4 billion—$23.2 billion and analyst expectations.
The company credited strong demand for smartphones and AI applications, driven by its advanced 3nm and 5nm technologies, with Needham&#8217;s Charles Shi noting <a target="_blank" href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" rel="noreferrer noopener">Apple as a key contributor</a>. Gross margin widened by 350 basis points to 57.8%. For the fourth quarter, Taiwan Semiconductor projects revenue of $26.1 billion—$26.9 billion, exceeding the Street&#8217;s forecast of $24.86 billion.
Taiwan Semiconductor stock gained over 98% year-to-date.
Price Actions: TSM stock is up 2.60% at $206.43 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Movers

Tech

Media

AAPL

NVDA

Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report

Truist Securities analyst Michael Swartz maintains Acushnet Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a Hold and raises the price target from $65 to $68.

GOLF

Truist Securities Maintains Hold on Acushnet Hldgs, Raises Price Target to $68

SKYE

Skye Bioscience shares are trading higher after the company reported better-than-expected Q3 EPS results.

Benchmark analyst Daniel Kurnos maintains Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) with a Buy and raises the price target from $21 to $23.

TGNA

Benchmark Maintains Buy on Tegna, Raises Price Target to $23

PSTX

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Mario Saric maintains Killam Apartment REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KMP#TSX">KMP</a>) with a Sector Perform and raises the price target from C$20.5 to C$21.

TSX:KMP

TSX:KMP/UN

Scotiabank Maintains Sector Perform on Killam Apartment REIT, Raises Price Target to C$21

Truist Securities analyst Neal Dingmann maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Buy and lowers the price target from $36 to $33.

Truist Securities Maintains Buy on APA, Lowers Price Target to $33

Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) co-founder Sergey Nazarov on Friday said &#8220;the party&#8217;s back on&#8221; for cryptocurrency markets, predicting substantial industry growth amid potential changes in the U.S. regulatory <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">landscape under Donald Trump&#8216;s presidency</a>.
What Happened: &#8220;This is just the beginning basically. This is like the party&#8217;s back on and there&#8217;s going to be huge huge growth in all categories of crypto,&#8221; Nazarov <a href="https://x.com/ChainLinkGod/status/1854553832396828796">told</a> CNBC, expressing optimism about the industry&#8217;s trajectory.
Nazarov emphasized that cryptocurrency&#8217;s fundamental benefits to society outweigh regulatory concerns. 
&#8220;I think that crypto fundamentally benefits society and makes things work in a much more reliable way than they do now,&#8221; he stated, citing <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41654131/pro-crypto-congress-in-2025-experts-see-stablecoins-as-key-area-for-advancement">stablecoins</a> and tokenized funds as examples of successful implementation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Drawing parallels with Asian crypto hubs, Nazarov pointed to successful regulatory frameworks in <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40901724/singapores-dbs-bank-launches-bitcoin-and-ethereum-options-trading-for-institutional-client">Singapore</a> and Hong Kong.
&#8220;More regulation doesn&#8217;t mean better markets, it just means kind of muted markets with less innovation,&#8221; he explained, advocating for a more permissive approach to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">cryptocurrency regulation</a>.
Price Action: Chainlink has followed other cryptocurrencies&#8217; uptrend since the start of October.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Price</td>
<td>1-day performance</td>
<td>7-day performance</td>
<td>30-day performance</td>
</tr>
<tr>
<td>$13.32</td>
<td>+8.6%</td>
<td>+14.7%</td>
<td>+25.6%</td>
</tr>
</tbody>
</table>
</figure>
The Chainlink co-founder&#8217;s perspectives align with growing institutional interest in digital assets, a topic that will be further explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814454/donald-trump-could-pardon-ross-ulbricht-january-6-protestors-and-one-other-controversial-f">Donald Trump Could Pardon Ross Ulbricht, January 6 Protestors And One Other Controversial Figure, Polymarket Traders Speculate</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LINK

'The Party's Back On'—Chainlink Co-Founder Predicts Major Crypto Growth Under Trump Presidency

Here are the major earnings after the close today

Pre-earnings options volume in Bausch Health (BHC) is normal with calls leading puts 10:3. Implied volatility suggests the market is anticipating a...

Bausch Health options imply 10.2% move in share price post-earnings

Bausch Health Companies (TSE:BHC) has released an update. Bausch Health Companies reported a strong third quarter of 2024, achieving a 12% increase...

Bausch Health Reports Strong Growth in Q3 2024

Bausch Health Companies GAAP EPS of -$0.23 misses by $0.37, revenue of $2.51B beats by $90M

Bausch Health raises 2024 revenue guidance

Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation

Bausch Health Companies ( ($BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its i...

Bausch Health Reports Growth Amid Improved Financials

Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies (BHC – Research Report) today and set a price target of $...

Truist Financial Keeps Their Hold Rating on Bausch Health Companies (BHC)

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated price target i...

Bausch Health Companies: Hold Rating Amid Mixed Financial Performance and Strategic Uncertainty

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly exploring a potential sale in ...

Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

ATEC

AXAHY

BECN

BKNG

BLCO

HOOD

HTGC

HUBG

IMAX

INVH

IRTC

JAKK

KLAC

LMND

LPLA

MATX

MSFT

PPSI

RIOT

ROOT

SBUX

SIMO

SNBR

SPOK

SPXC

SSNLF

STAA

STEM

TDOC

TENB

Legal

Press Releases

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

Management

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Bausch Health Responds to Market Rumors

Bausch Health Announces Second Quarter 2024 Results

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Events

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Comments

Bausch Health Companies

Bausch Health Companies (BHC) Opzioni

Bausch Health Companies (NYSE:BHC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO